Immunologic Research

, Volume 61, Issue 1–2, pp 164–168 | Cite as

Tocilizumab-induced neutropenia in rheumatoid arthritis patients with previous history of neutropenia: case series and review of literature

DIAGNOSTICS AND ENVIRONMENTAL FACTORS
First Online:

Abstract

One of the adverse events of tocilizumab (TCZ) is a transient, dose-dependent neutropenia. The recommendations of the Summary of Product Characteristics state that this neutropenia should be managed according to the absolute neutrophil count (ANC). However, the approach to a patient who had a history of neutropenia induced by previous DMARDs and developed TCZ-induced neutropenia remains unclear. We would like to report a series of four patients with rheumatoid arthritis who developed Grade 2 neutropenia (ANC 1–1.5 × 109/L) following intravenous TCZ treatment at a dose of 8 mg/kg. All of them had a previous history of neutropenia (Grade 2 or Grade 3) due to Etanercept (three patients) and Sulfasalazine (one patient). Therefore, we decided to decrease the TCZ dosage by 10–20 % approximately. Reducing of the dosage did not have any influence on the efficacy of TCZ, and all of our patients remained in clinical remission. The mechanisms underlying neutropenia induced by Tocilizumab, Etanercept and Sulfasalazine are also discussed in this article.

Keywords

Tocilizumab Rheumatoid arthritis Neutropenia 
This is a preview of subscription content, log in to check access.

Notes

Conflict of interest

The authors have no conflicts of interest to declare.

References

  1. 1.
    Maini RN, Taylor PC, Szechinski J et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2008;58:887. Erratum in: Arthritis Rheum. 2008;58:887.Google Scholar
  2. 2.
    Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58:2968–80.PubMedCrossRefGoogle Scholar
  3. 3.
    Emery P, Keystone E, Tony HP et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516–23. Erratum in: Ann Rheum Dis. 2009;68:296.Google Scholar
  4. 4.
    Oldfield V, Dhillon S, Plosker GL. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs 2009;69:609–32.Google Scholar
  5. 5.
    Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol. 2010;20:222–32.PubMedCrossRefGoogle Scholar
  6. 6.
    Nakamura I, Omata Y, Naito M, et al. Blockade of interleukin 6 signaling induces marked neutropenia in patients with rheumatoid arthritis. J Rheumatol. 2009;36:459–60.PubMedCrossRefGoogle Scholar
  7. 7.
    European Medicines Agency. RoActemra (tocilizumab). Summary of Product Characteristics. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000955/WC500054890.pdf. Accessed 1 Sept 2014.
  8. 8.
    De Benedetti F, Ruperto N, Baildam E, et al. A14: neutropenia with tocilizumab treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2014;66:S23–4.CrossRefGoogle Scholar
  9. 9.
    Benedetti FD, Rubio-Pérez N, Salazar CD, et al. A45: neutropenia with tocilizumab treatment is not associated with increased infection risk in patients with polyarticular-course juvenile idiopathic arthritis. Arthritis Rheumatol. 2014;66:S67–8.CrossRefGoogle Scholar
  10. 10.
    Montané E, Sallés M, Barriocanal A, et al. Antitumor necrosis factor-induced neutropenia: a case report with double positive rechallenges. Clin Rheumatol. 2007;26:1527–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Wenham C, Gadsby K, Deighton C. Three significant cases of neutropenia with etanercept. Rheumatology (Oxford). 2008;47:376–7.CrossRefGoogle Scholar
  12. 12.
    Ottaviani S, Cerf-Payrastre I, Kemiche F, et al. Adalimumab-induced neutropenia in a patient with rheumatoid arthritis. Joint Bone Spine. 2009;76:312–3.PubMedCrossRefGoogle Scholar
  13. 13.
    Rajakulendran S, Gadsby K, Allen D, et al. Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis. Ann Rheum Dis. 2006;65:1678–9.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Haroon M, Daly M, Harney S. Re-challenge with Etanercept in patients with Etanercept-induced Neutropenia. Clin Rheumatol. 2012;31:151–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Hastings R, Ding T, Butt S, et al. Neutropenia in patients receiving anti-tumor necrosis factor therapy. Arthritis Care Res (Hoboken). 2010;62:764–9.CrossRefGoogle Scholar
  16. 16.
    Szalay B, Acs L, Vásárhelyi B, et al. Successful use of tocilizumab in a patient with rheumatoid arthritis following severe pancytopenia during etanercept therapy. J Clin Rheumatol. 2011;17:377–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Nagamine R, Chen W, Hara T, et al. Immediate reduction of white blood cell count after tocilizumab administration was observed in some cases. Mod Rheumatol. 2009;19:348–50.PubMedCrossRefGoogle Scholar
  18. 18.
    Nishimoto N1, Yoshizaki K, Maeda K et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol. 2003;30:1426–35.Google Scholar
  19. 19.
    Wright HL, Cross AL, Edwards SW, et al. Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo. Rheumatology (Oxford). 2014;53:1321–31.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Zabludowicz Center for Autoimmune DiseasesChaim Sheba Medical CenterTel-HashomerIsrael
  2. 2.Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Sackler Faculty of MedicineTel-Aviv UniversityTel-AvivIsrael
  3. 3.Tel-Aviv UniversityTel-AvivIsrael

Personalised recommendations